+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hypercholesterolemia Drug"

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update - Product Thumbnail Image

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

  • Report
  • May 2022
  • 471 Pages
  • Global
From
Hypercholesterolemia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update - Product Thumbnail Image

Hypercholesterolemia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

  • Report
  • March 2022
  • 1284 Pages
  • Global
From
Homozygous Familial Hypercholesterolemia (HoFH) - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Homozygous Familial Hypercholesterolemia (HoFH) - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • November 2021
  • 259 Pages
  • Global
From
Global Familial Hypercholesterolemia Clinical Trial Pipeline Highlights - 2022 - Product Thumbnail Image

Global Familial Hypercholesterolemia Clinical Trial Pipeline Highlights - 2022

  • Report
  • August 2022
  • Global
From
Hypercholesterolemia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Hypercholesterolemia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2024
  • 80 Pages
  • Global
From
Heterozygous Familial Hypercholesterolemia Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type - Product Thumbnail Image

Heterozygous Familial Hypercholesterolemia Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • July 2023
  • 73 Pages
  • Global
From
Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 210 Pages
  • Global
From
Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 63 Pages
  • Global
From
Homozygous Familial Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Homozygous Familial Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 51 Pages
  • Global
From
Familial Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Familial Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 63 Pages
  • Global
From
Loading Indicator

The Hypercholesterolemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high cholesterol levels. Hypercholesterolemia drugs are used to reduce the amount of cholesterol in the blood, which can help reduce the risk of heart attack and stroke. These drugs are typically prescribed to patients with high cholesterol levels, or those at risk of developing cardiovascular disease. Commonly prescribed drugs include statins, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. The Hypercholesterolemia Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Sanofi, AstraZeneca, Novartis, and Bristol-Myers Squibb. Show Less Read more